Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
One in three adults with major depressive disorder (MDD) do not experience clinically significant improvement after multiple sequential courses of antidepressants and have treatment-resistant depression (TRD). The presence of TRD contributes to the morbidity and excess mortality associated with MDD and has been linked to significantly increased health care expenses. In the absence of a consensus definition of TRD, this report takes a broad approach by considering inadequate response to one or more courses of antidepressants and focuses on atypical antipsychotics that are approved by the U.S. Food and Drug Administration for treatment of depression (aripiprazole, brexpiprazole, cariprazine, extended-release quetiapine, and olanzapine-fluoxetine combination). While multiple acute-phase studies have demonstrated the efficacy of these medications in improving depressive symptoms, clinically meaningful improvement (i.e., remission) remains limited, with significant concerns about side effects (including weight gain, metabolic dysfunction, extrapyramidal symptoms, and tardive dyskinesia), especially with long-term use. With the rapidly evolving landscape of antidepressant treatments over the past few years, which has witnessed approval of rapid-acting antidepressants (e.g., esketamine nasal spray and dextromethorphan-bupropion combination) and several more in the late-stage pipeline (e.g., zuranolone and psilocybin), it remains to be seen whether the use of atypical antipsychotics will go the way of the older and rarely prescribed antidepressants (such as tricyclics and monoamine oxidase inhibitors). Pragmatic clinical trials are needed to compare the effectiveness of atypical antipsychotics with TRD-specific pharmacotherapies and neuromodulation treatments and to identify the optimal sequencing of these varied approaches for patients with MDD. When using atypical antipsychotics, clinicians and patients are encouraged to use a shared decision-making approach by personalizing treatment selection based on anticipated side effects, tolerability, cost, and feasibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167
Research works printed but not linked: 57
- 10.1371/journal.pone.0223255 · DOI
- Lundberg J, JAMA Psychiatry
- Scott F, J Psychopharmacol
- 10.1007/s40801-022-00316-4 · DOI
- 10.1016/j.jad.2022.03.058 · DOI
- 10.1002/da.23138 · DOI
- 10.1176/appi.ajp.2021.21101034 · DOI
- 10.1176/appi.ajp.2018.18030355 · DOI
- 10.1176/appi.ajp.2016.16020176 · DOI · Paper page
- Jha MK, 2018, Focus (Am Psychiatr Publ), 16, 279
- 10.4088/JCP.11ac07225 · DOI · Paper page
- 10.1016/j.jad.2004.01.015 · DOI · Paper page
- 10.1038/s41386-018-0180-z · DOI
- 10.1186/s12890-017-0522-3 · DOI
- 10.4088/JCP.20m13740 · DOI
- 10.1371/journal.pone.0076882 · DOI · Paper page
- 10.3389/fpsyt.2021.643609 · DOI
- 10.4088/JCP.v68n0604 · DOI · Paper page
- 10.1016/j.jad.2013.07.035 · DOI · Paper page
- 10.1111/pcn.12663 · DOI
- 10.4088/JCP.14m09689 · DOI · Paper page
- 10.1080/03007995.2018.1430220 · DOI
- 10.4088/JCP.17m12058 · DOI
- 10.1017/neu.2018.23 · DOI
- Nemeroff CB, 2002, J Clin Psychiatry, 63, 5
- 10.1038/sj.npp.1301646 · DOI · Paper page
- 10.1017/S1461145710000015 · DOI · Paper page
- 10.1016/j.jad.2010.08.032 · DOI
- 10.1002/da.20740 · DOI · Paper page
- 10.1371/journal.pone.0216044 · DOI
- 10.1007/s00213-016-4382-y · DOI
- 10.1097/YIC.0000000000000235 · DOI · Paper page
- Earley WR, 2018, Psychopharmacol Bull, 48, 62
- Sachs GS, 2023, Am J Psychiatry, 180, 241, 10.1176/appi.ajp.20220504 · DOI
- 10.2165/00023210-200418040-00005 · DOI · Paper page
- 10.1124/jpet.109.160432 · DOI · Paper page
- 10.1007/s13318-020-00650-4 · DOI
- 10.2147/DDDT.S95100 · DOI
- Dean RL, 2021, Cochrane Database Syst Rev, 9, Cd011612
- 10.4088/JCP.21r14086 · DOI
- 10.1176/appi.ajp.21111086 · DOI
- 10.1016/j.biopsych.2009.08.038 · DOI · Paper page
- 10.1177/0004867416631828 · DOI
- 10.1093/ijnp/pyaa027 · DOI
- 10.1017/S1461145709000169 · DOI · Paper page
- 10.1159/000457960 · DOI
- 10.1093/ijnp/pyab050 · DOI
- 10.1176/appi.ajp.2021.21020197 · DOI · Paper page
- 10.1038/s41380-018-0284-1 · DOI · Paper page
- 10.4088/JCP.19m12928 · DOI · Paper page
- Dirks B, 2022, Psychopharmacol Bull, 52, 8
- 10.2174/1570159X14666160321122703 · DOI · Paper page
- 10.1176/appi.ajp.2015.14101251 · DOI
- 10.1001/jamapsychiatry.2021.4281 · DOI
- 10.1056/NEJMoa1911772 · DOI · Paper page
- 10.1016/S0140-6736(22)01990-0 · DOI
- 10.1056/NEJMoa2017015 · DOI · Paper page
Cited by
Saelens, J., Gramser, A., Watzal, V., Zarate, C. A., Lanzenberger, R., & Kraus, C. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-02044-5 · Cited by 51
Psychopharmacological Treatment of Depression and Anxiety and their Different Drug Delivery Targets
Sharma, A., Alam, M. A., Kaur, A., Sharma, S., & Yadav, S. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/2666082219666230822140902 · Cited by 3
Liu, J., Lu, Y., Bhuiyan, P., Gruttner, J., St. Louis, L., Yi, Y., Liang, G., & Wei, H. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03816-x · Cited by 2
Yang, X., Gao, Y.-Y., Xu, S.-Q., Wang, J.-C., Ma, Y.-J., Jiao, L.-H., Wang, L., Wang, X.-Y., Bashir, S., An, C.-X., et al. (2025) · World Journal of Meta-Analysis · doi:10.13105/wjma.v13.i1.99971 · Cited by 1
Metadata
- Authors
- Jha, M. K., & Mathew, S. J.
- Venue
- American Journal of Psychiatry
- Published
- 2023-03-01
- Volume
- 180
- Issue
- 3
- Pages
- 190-199
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4322719045
- Cited by
- 114
- References
- 51
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. https://app.cochat.ai/papers/10.1176/appi.ajp.20230025
- The paper
- Jha, M. K., & Mathew, S. J. (2023). Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.20230025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.